Resmed (NYSE: RMD; ASX: RMD) has completed the sale of its MatrixCare business to Frazier Healthcare Partners in a $490 million all-cash transaction, subject to customary closing adjustments. The divestiture narrows the medical-technology company’s portfolio around sleep health, breathing health and connected home-based care.
MatrixCare supplies software to more than 15,000 providers across skilled nursing, senior living, life-plan communities, home health and hospice. The transaction also includes software offerings sold under the Healthcare First and Citus brands, as well as related home-health and hospice solutions.
Why the Resmed MatrixCare Sale Matters for Capital Allocation
The Resmed MatrixCare sale gives management additional capacity to invest in product innovation and return capital to shareholders. When the agreement was announced, the company said net proceeds would support an accelerated share-repurchase program and general corporate purposes.
MatrixCare generated approximately $220 million of revenue and $55 million of non-GAAP operating profit in Resmed’s 2026 fiscal year, according to transaction disclosures. Those figures provide a benchmark for the earnings contribution leaving the group and the capital that management must redeploy to create value after the sale.
The divestiture excludes Resmed’s Brightree software business in the United States and MEDIFOX DAN in Germany. Retaining those platforms allows the company to continue participating in digital healthcare workflows that are more closely connected with its core sleep and respiratory-care strategy.
Frazier Takes Control of a Large Post-Acute Software Platform
Frazier Healthcare Partners is acquiring a broad software platform serving post-acute and long-term-care providers. The investment firm has said it plans to support product innovation under dedicated ownership, while transition-service arrangements are intended to preserve continuity across systems and day-to-day operations after closing.
For Resmed, the strategic rationale is greater focus. Management has argued that concentrating resources on scalable sleep, breathing and connected-care opportunities should improve execution under its 2030 strategy. The company will still need to offset the earnings contribution lost through the sale and demonstrate disciplined use of the cash proceeds.
The Resmed MatrixCare sale therefore represents both a portfolio simplification and a capital-allocation test. Investors will be watching the size and timing of shareholder returns, the performance of the retained software assets and whether greater focus translates into faster growth across Resmed’s core medical-device and digital-health businesses.
